ArticleBMC cancer2026
FOXM1-associated melanoma stratification: integrated multi-omics and experimental validation reveal prognostic significance and therapeutic potential.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCutaneous melanoma is a highly aggressive malignancy characterized by marked biological heterogeneity and variable clinical outcomes. Reliable biomarkers for prognostic stratification and biological characterization remain limited. This study aimed to investigate the expression pattern, prognostic significance, immune associations, and functional relevance of Forkhead box M1 (FOXM1) in melanoma.
methodsMulti-omics analyses were performed using TCGA, GTEx, GEO, and Human Protein Atlas datasets. Survival analysis, Cox regression, nomogram construction, functional enrichment, immune infiltration, genomic alteration, and drug sensitivity analyses were conducted. FOXM1 expression was further validated by immunohistochemistry. Functional experiments, including qRT-PCR, Western blotting, CCK-8 proliferation assays, and Transwell migration and invasion assays, were performed following FOXM1 knockdown in A375 melanoma cells.
resultsFOXM1 was significantly overexpressed in melanoma and independently associated with poor overall survival. A FOXM1-based prognostic model demonstrated satisfactory predictive performance. Functional analyses indicated that FOXM1 was primarily involved in cell-cycle progression and mitotic regulation. High FOXM1 expression was associated with an immunosuppressive microenvironment characterized by reduced cytotoxic immune infiltration and altered immune scores. Genomic analysis suggested copy-number amplification as a major contributor to FOXM1 overexpression. In vitro experiments confirmed efficient FOXM1 silencing and demonstrated that FOXM1 knockdown significantly inhibited melanoma cell proliferation, migration, and invasion.
conclusionsFOXM1 is a prognostically relevant and immune-associated biomarker in melanoma. Its overexpression is associated with aggressive tumor behavior, and functional inhibition suppresses malignant phenotypes, highlighting its potential value for risk stratification and therapeutic targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.